Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motixafortide - Biokine Therapeutics/BioLineRx

Drug Profile

Motixafortide - Biokine Therapeutics/BioLineRx

Alternative Names: 4F-Benzoyl-TN14003; APHEXDA; BKT-140; BL-8040; GFH-168; TF-14016; TN-14003

Latest Information Update: 04 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Genentech; Merck & Co
  • Class Antianaemics; Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action Apoptosis stimulants; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Pancreatic cancer; Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stem cell mobilisation
  • Phase II Acute myeloid leukaemia; Aplastic anaemia; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Gastric cancer
  • No development reported Adult respiratory distress syndrome
  • Discontinued Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 30 May 2024 BioLineRx in collaboration with St. Jude Children's Research Hospital plans a phase I trial for Sickle cell disease in the next few months (SC)
  • 24 May 2024 Efficacy and pharmacodynamics data from the phase II CheMo4METPANC trial in Pancreatic cancer released by BioLineRx
  • 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top